OPM Secures $1.2M in Funding for Purchase of EOSINT P 800 SLS Machine for Fabrication of Medical Implants and Other High-Value Devices

Share Article

Equipment to be installed in new state-of-the-art facility in South Windsor, Connecticut.

OXPEKK OsteoFab Mastoid

Mastoid structure created through the OXPEKK® OsteoFab™ manufacturing process

This particular undertaking will further position our firm and the state on the leading edge of biomedical and manufacturing technologies.

OPM is very pleased to announce it has secured funding for the purchase of an EOSINT P 800 SLS machine for the production of the firm’s OsteoFab™ medical implants. The funding was provided by the Connecticut Innovations, Inc.’s BioScience Facilities Fund. Financing is in the form of special debt instrument. The equipment is part of a multi-million dollar project to produce medical implants through additive fabrication with the firm’s proprietary OXPEKK® products which have properties comparable to human bone. The facility will be certified to ISO 13485, ISO 9001 and AS9100 and be equipped with clean rooms and world-class design and inspection capabilities. The project is expected to be completed by September 2011.

“We are very pleased that CI has provided the funding via their BioScience Facilities Fund for this extremely important project. We have had a long, successful relationship with CI that has resulted in positive financial return on their previous investment and the growth of jobs and world class technologies in the state,” said Scott DeFelice, President of OPM. “We are exceedingly confident that this particular undertaking will further position our firm and the state on the leading edge of biomedical and manufacturing technologies.”

OPM currently sells its biomedical polymeric OXPEKK® products on a global basis with regulatory approvals from the FDA, KFDA, ANVISA, COFEPRIS, and several CE Marks. It has traditionally sold these products as raw materials. With the addition of the EOSINT P 800, however, it will now be able to provide value-added manufacturing in-house. The P 800 allows for direct digital additive manufacturing through selective laser sintering (SLS), which means nearly anything that can be designed can be built with the firm’s implantable polymer. This enhanced capability positions the firm to lead innovation in biomedical technologies and the polymer market. The initial focus of the firm’s efforts will be the production of custom cranial and maxillofacial implants which are anatomically identical implants derived directly from a CT scan or MRI.

About OPM

Founded in 2000 OPM is a privately held advanced materials and manufacturing technology company focused on developing solutions that enhance fundamental human sustainability.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Scott Defelice